Furthermore, the current experience with immunotherapy using anti-programmed cell death protein 1 (PD-1) antibodies as single agents has generally led to disappointing results in both selected or mixed sarcoma histologies (Burgess and Tawbi, 2015; Ben-Ami et al., 2017; Tawbi et al., 2017; Toulmonde et al., 2018). This evidence concerns the gene PDCD1 and sarcoma.